On April 30, 2018, the first Zostavax shingles vaccine lawsuit was filed since the vaccine’s maker, Merck, Inc., requested the exponentially growing number of cases be consolidated into one Court.

The lawsuit, brought by a South Carolina resident, alleges he began experiencing loss of vision in his left eye two months after receiving the Zostavax vaccine. He was diagnosed with retinal necrosis, or tissue decay in his retina, likely due to the VZV virus.

The FDA approved Zostavax as a supposed immunization against the shingles virus in 2006. Since then, Zostavax has been injected into over 36 million Americans, earning Merck, Inc. approximately $685 million per year.

Since its approval, thousands of Zostavax lawsuits have been filed across the nation, alleging that Merck’s Zostavax shingles vaccine causes viral injuries such as loss of eyesight, complete and permanent hearing loss, and the shingles virus itself. The number of lawsuits regarding Zostavax has risen quickly – forcing Merck to request that the cases be consolidated into a Multi-District Litigation in front of one District Judge. Thousands more lawsuits are expected to be filed in the coming months.

If you or a loved one was injected with the Zostavax shingles vaccine and experienced loss of eyesight, loss of hearing, or another serious viral injury, contact The Potts Law Firm for your free consultation with one of our Zostavax lawyers. We maintain a staff of highly accredited lawyers, medical directors and physicians and are fully equipped to handle your case. You pay nothing in attorney fees unless we win your case.


Comments are closed